Article
Differential oncogenic potential of activated RAS isoforms in melanocytes.
Oncogene - 5 Jul 2007
Whitwam T, Vanbrocklin M W, Russo M E, Haak P T, Bilgili D, Resau J H, Koo H-M, Holmen S L
Abstract excerpt
RAS genes are mutated in approximately 30% of all human cancers. Interestingly, there exists a strong bias in favor of mutation of only one of the three major RAS genes in tumors of different cellular origins. NRAS mutations occur in approximately 20% of human melanomas, whereas HRAS and KRAS mutations are rare in this disease. To define the mechanism(s) responsible for this preference in melanocytes, we compared...
Topics
- Cell Line, Tumor
- Cell Proliferation
- Cell Transformation, Neoplastic
- Cyclin-Dependent Kinase Inhibitor p16
- Genes, ras
- Humans
- Melanocytes
- Melanoma
- Mutation
- Protein Isoforms
- Proto-Oncogene Proteins c-myc